Tempero Bio News and Activities

Tempero Bio is owned by Aditum Bio.

They are in:

• Fund50%
• Biotechnology50%

Acquisition, funding and merger involving Aditum Bio.

• Tempero Bio has filed for bankruptcy protection  (posted on April 29 2026).
• Tempero Bio has just announced a $70 Million fundraising (posted on March 25 2025).

View the org chart displaying its 9 main executives

Most searched biographies at Tempero Bio

• Paul Johnson, Chief Executive Officer
• Francisco Gimenez, Director
• Joe Jimenez, Director

Popular executive movements at Tempero Bio

• Zak Huang has joined the company as Senior Vice President, Regulatory Affairs  (posted on October 24 2025).
• Ella Kleynerman, who was Director, Clinical Operations, is promoted to Senior Director, Clinical Operations  (posted on September 26 2025).

Create your alert
to follow the executive moves at Tempero Bio.

Aditum Bio has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Tempero Bio

• News | Aditum Bio

Social media about Tempero Bio

• Tempero Bio on Wikipedia, Google News & Yahoo Finance
• Tempero Bio on LinkedIn, X (Twitter) & YouTube